Form 4: Xylem Inc. Executive Meredith Emmerich Awarded Stock Options and Restricted Stock Units
SEC Form 4 Filing
Meredith Emmerich, SVP & President of AW at Xylem Inc., received stock options and restricted stock units on October 21, 2024, according to a Form 4 filing.
Summary
- Meredith Emmerich, a Senior Vice President & President, AW at Xylem Inc., was granted stock options and restricted stock units on October 21, 2024.
- The stock options allow Emmerich to purchase 33,138 shares of Xylem Inc. common stock at an exercise price of $132.54 per share.
- These options vest in one-third increments annually, starting October 21, 2025, and expiring on October 21, 2034.
- Emmerich also received 3,772 restricted stock units, which will vest in two equal installments on October 21, 2025, and October 21, 2026.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating a stable and incentivized management structure. The sentiment is neutral to positive as it suggests alignment of interests between management and shareholders.
Positives
- The grant of stock options and restricted stock units aligns Emmerich's interests with those of Xylem Inc.'s shareholders.
- The vesting schedule encourages long-term performance and retention of a key executive.
Future Outlook
The vesting schedules for the stock options and restricted stock units suggest a focus on long-term value creation and executive retention.
Industry Context
Stock option and restricted stock unit grants are a common practice in executive compensation packages within publicly traded companies to incentivize performance and align executive interests with shareholder value.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are common across publicly traded companies like Xylem Inc.
- Companies such as Danaher, Roper Technologies, and Advanced Drainage Systems also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules and exercise prices are generally structured to align with industry benchmarks for performance and retention.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize management to improve company performance.
- Employees may see this as a positive sign of investment in leadership and company growth.
Key Dates
| Date | Description |
|---|---|
| 10/21/2024 | Date of the transaction: grant of stock options and restricted stock units. |
| 02/24/2016 | Date of the Amended and Restated Xylem 2011 Omnibus Incentive Plan |
| 10/21/2025 | First vesting date for one-third of the stock options and one-half of the restricted stock units. |
| 10/21/2026 | Second vesting date for one-third of the stock options and one-half of the restricted stock units. |
| 10/21/2027 | Final vesting date for one-third of the stock options. |
| 10/21/2034 | Expiration date of the stock options. |
| 10/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.